Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 17;9:1541. doi: 10.3389/fonc.2019.01541

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Sonkusre.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

(A,B) Real-time gene expression profiling of SeNPs treated and untreated LNCaP cells was performed. Significant dose-dependent fold change (^*p < 0.05, ^**p < 0.01, and ^***p < 0.001) was observed in the expression of IRF1, TNF, PSA, and AR gene in LNCaP cells on SeNP treatment. The experiment was conducted in triplicate. (C) LNCaP cells were cultured in the presence of 2 μg Se/ml SeNPs along with 20, 50, or 100 μM Necrostatin-1 for 24 h. Cell viability determined with MTT assay showed more viable cells in wells treated with SeNP along with Necrostatin-1 compared to SeNP treated cells. Cell viability was directly proportional to the concentration of Necrostatin-1 used. The results were confirmed by three repetitions of experiments and each experiment was conducted in triplicate. ^****p < 0.0001 represents a significant difference in the viability of LNCaP cell treated with SeNP or SeNP with 100 μM Necrostatin-1.